sacituzumab govitecan

Immunomedics' Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
Immunomedics' Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
BioSpace
Immunomeedics
sacituzumab govitecan
clinical trials
breast cancer
triple negative breast cancer
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Troubled Immunomedics tries again at FDA after rejection
Troubled Immunomedics tries again at FDA after rejection
Fierce Biotech
Immunomedics
IMMU-132
sacituzumab govitecan
FDA
metastatic triple-negative breast cancer
Flag link:
After FDA rejection, Immunomedics tries again with breast cancer drug
After FDA rejection, Immunomedics tries again with breast cancer drug
Biopharma Dive
Immunomedics
breast cancer
sacituzumab govitecan
metastatic triple-negative breast cancer
FDA
Flag link:
2 Biotechs With Approaching Drug Approvals
2 Biotechs With Approaching Drug Approvals
Motley Fool
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
Flag link:
With Immunomedics ADC deal, Everest bolsters cancer pipeline
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
Flag link:
FDA uncovers data manipulation at Immunomedics plant making cancer drug
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Flag link:
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Immunomedics
FDA
sacituzumab govitecan
Flag link:
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Immunomedics
FDA
breast cancer
sacituzumab govitecan
Flag link:
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Flag link:
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
Flag link:
6 Key Cancer Winners From ASCO Presentations
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma
Flag link:
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Patients With Advanced Breast, Lung, Esophageal, and Colorectal Cancers Respond to Immunomedics' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments
Yahoo
Immunomedics
chemotherapy
breast cancer
lung cancer
esophageal cancer
colorectal cancer
sacituzumab govitecan
Flag link: